REL and graft versus host disease: Studies on the c-Rel inhibitor IT-603 showed ameliorating effects on GVHD, mediated through reduced alloreactivity, defective gut homing and impaired negative feedback on IL-2 production by effector T cells leading to an expansion of regulatory T cells.